Explore 3 Stock Ideas & Industry Insights Download Free Report

Ambrx Biopharma Inc. American Depositary Shares

Company price
None USD 0.00(0%)
Last update at 2024-04-09T03:57:33.445240Z
Market Cap
918.20M
P/E
33.81

Momentum Score

…

Ambrx Biopharma Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing antibody drug conjugates (ADCs) and other engineered therapies to modulate the immune system. It focuses on portfolio of clinical and preclinical programs designed to optimize efficacy and safety in multiple cancer indications, including ARX517, its proprietary antibody-drug conjugate (ADC) targeting the prostate-specific membrane antigen (PSMA) and ARX788, its proprietary ADC targeting HER2. The company also has preclinical and clinical collaborations with multiple partners on drug candidates using Ambrx technology. The company was incorporated in 2003 and is headquartered in La Jolla, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
1.28
Low
16.86
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
-
Dividend Yield
-
Revenue TTM
4.09M
Revenue Per Share
0.01
Gross Profit TTM
7.40M
Debt / Equity
0.10
ROE
-37.23%
Net Debt
-43.63M
ROCE
-43.80%
Diluted EPS TTM
0.43

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax -76.06M -68.29M -17.84M -22.32M
Minority interest 0.00M 0.21M 1.29M 2.56M
Net income -78.00M -68.29M -17.84M -22.31M
Selling general administrative 20.33M 17.07M 6.35M 6.40M
Selling and marketing expenses 2.73M 1.44M - -
Gross profit 7.40M 7.46M 13.67M 10.31M
Reconciled depreciation 1.80M 2.15M 1.94M 2.05M
Ebit -57.08M -64.42M -13.12M -22.47M
Ebitda -55.79M -62.27M -11.17M -20.42M
Depreciation and amortization 1.29M 2.15M 1.94M 2.05M
Operating income -57.08M -64.42M -13.12M -22.47M
Other operating expenses 83.83M 71.88M 26.79M 32.78M
Interest expense 0.97M 3.65M 3.43M 2.41M
Tax provision 1.94M 0.00M 0.00M -0.00M
Interest income - 0.00M 0.03M 0.20M
Net interest income -0.97M 0.00M 0.03M 0.20M
Income tax expense 1.94M 0.00M 0.00M -0.00M
Total revenue 7.40M 7.46M 13.67M 10.31M
Total operating expenses 74.14M 71.88M 26.79M 32.78M
Total other income expense net -18.98M -3.86M -4.72M 0.16M
Net income from continuing ops -78.00M -68.29M -17.84M -22.31M
Net income applicable to common shares -78.00M -68.08M -16.54M -20.06M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 146.98M 229.02M 134.02M 61.73M
Intangible assets 25.25M 35.96M 36.83M 38.28M
Other current assets 0.32M 0.23M 0.19M 0.15M
Total liab 29.13M 39.05M 272.17M 25.74M
Total stockholder equity 117.85M 189.97M -139.43M 33.42M
Other current liab 11.31M 14.12M 2.38M 3.88M
Common stock 0.03M 0.03M - 0.01M
Capital stock 0.03M 0.03M 0.00M 0.01M
Retained earnings -291.63M -213.63M -145.55M -129.01M
Other liab 2.22M 2.26M 4.28M 7.61M
Other assets 0.34M 0.53M 0.62M 0.32M
Cash 55.61M 170.06M 90.46M 15.49M
Total current liabilities 16.66M 24.58M 13.26M 14.94M
Current deferred revenue 0.41M 4.27M 6.47M 4.21M
Net debt -43.63M -156.94M -87.27M -10.85M
Short term debt 1.73M 0.92M 1.59M 1.45M
Short long term debt total 11.98M 13.13M 3.19M 4.65M
Other stockholder equity 410.75M 404.36M 6.80M 163.26M
Property plant equipment 14.01M 15.72M 3.49M 4.97M
Total current assets 90.58M 176.81M 93.08M 18.16M
Long term investments 16.79M - - -
Net tangible assets 92.60M 154.00M -176.26M -4.86M
Short term investments 28.87M - - -
Net receivables 2.05M 1.34M 0.98M 1.39M
Inventory 3.73M 5.17M 1.44M 1.13M
Accounts payable 3.21M 5.27M 2.82M 5.39M
Accumulated other comprehensive income -1.30M -0.79M -0.69M -0.84M
Common stock total equity - - - 0.01M
Non currrent assets other 0.34M 0.53M 0.62M 0.32M
Non current assets total 56.39M 52.21M 40.94M 43.57M
Capital lease obligations 11.98M 13.13M 3.19M 4.65M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments -46.72M -3.21M -0.25M -0.05M
Change to liabilities -5.73M -1.68M -4.53M 14.79M
Total cashflows from investing activities -46.72M -3.21M -0.25M -0.05M
Total cash from financing activities 0.93M 127.43M 95.68M 95.68M
Change to operating activities -5.76M 6.13M -3.26M 0.15M
Net income -78.00M -68.29M -17.84M -22.31M
Change in cash -114.47M 79.63M 75.02M -2.85M
Begin period cash flow 170.91M 91.28M 16.26M 19.11M
End period cash flow 56.44M 170.91M 91.28M 16.26M
Total cash from operating activities -68.67M -44.64M -20.58M -2.77M
Issuance of capital stock 0.14M 148.73M 95.68M 0.00M
Depreciation 1.80M 2.15M 1.94M 2.05M
Change to inventory - 6.13M -3.26M 0.15M
Change to account receivables 0.86M -0.81M 0.41M -0.76M
Other cashflows from financing activities 166.79M -21.30M 97.02M -0.05M
Change to netincome 18.65M 17.64M 1.40M 1.07M
Capital expenditures 1.05M 3.21M 0.25M 0.05M
Change in working capital -10.62M 3.64M -7.38M 14.18M
Stock based compensation 6.25M 11.86M 1.22M 1.83M
Other non cash items 11.89M 5.49M 1.48M 1.48M
Free cash flow -69.73M -47.85M -20.83M -2.81M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
NVO
Novo Nordisk A/S
-1.06
2.73%
37.81 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc
-5.64
1.08%
515.02 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc
-
-%
920.69 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE
-
-%
965.00 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Ambrx Biopharma Inc. American Depositary Shares

Ambrx Biopharma Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing antibody drug conjugates (ADCs) and other engineered therapies to modulate the immune system. It focuses on portfolio of clinical and preclinical programs designed to optimize efficacy and safety in multiple cancer indications, including ARX517, its proprietary antibody-drug conjugate (ADC) targeting the prostate-specific membrane antigen (PSMA) and ARX788, its proprietary ADC targeting HER2. The company also has preclinical and clinical collaborations with multiple partners on drug candidates using Ambrx technology. The company was incorporated in 2003 and is headquartered in La Jolla, California.

10975 North Torrey Pines Road, La Jolla, CA, United States, 92037

858 875 2400

87

Name Title Year Born
Ms. Sonja Nelson CPA Chief Financial & Operating Officer 1973
Mr. Daniel J. O'Connor J.D. CEO, Pres & Director 1965
Dr. Ying J. Buechler Ph.D. Chief Technology Officer NA
Dr. Shawn Shao-Hui Zhang Ph.D. Chief Scientific Officer NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…